These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38852689)

  • 1. Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions.
    Leishman DJ; Brimecombe J; Crumb W; Hebeisen S; Jenkinson S; Kilfoil PJ; Matsukawa H; Melliti K; Qu Y
    J Pharmacol Toxicol Methods; 2024; 128():107524. PubMed ID: 38852689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the hERG safety margin after 20 years of routine hERG screening.
    Leishman DJ; Abernathy MM; Wang EB
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of gefitinib-induced QT prolongation.
    Jie LJ; Li YD; Zhang HQ; Mao L; Xie HB; Zhou FG; Zhou TL; Xie D; Lin JL; Li GY; Cai BN; Zhang YH; Wang Y
    Eur J Pharmacol; 2021 Nov; 910():174441. PubMed ID: 34474028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm.
    Ridder BJ; Leishman DJ; Bridgland-Taylor M; Samieegohar M; Han X; Wu WW; Randolph A; Tran P; Sheng J; Danker T; Lindqvist A; Konrad D; Hebeisen S; Polonchuk L; Gissinger E; Renganathan M; Koci B; Wei H; Fan J; Levesque P; Kwagh J; Imredy J; Zhai J; Rogers M; Humphries E; Kirby R; Stoelzle-Feix S; Brinkwirth N; Rotordam MG; Becker N; Friis S; Rapedius M; Goetze TA; Strassmaier T; Okeyo G; Kramer J; Kuryshev Y; Wu C; Himmel H; Mirams GR; Strauss DG; Bardenet R; Li Z
    Toxicol Appl Pharmacol; 2020 May; 394():114961. PubMed ID: 32209365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
    Silvestre JS; O'Neill MF; Prous JR
    J Psychopharmacol; 2014 Apr; 28(4):329-40. PubMed ID: 24327451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
    Gintant G
    Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature.
    El Sherbini A; Liblik K; Lee J; Baranchuk A; Zhang S; El-Diasty M
    Trends Cardiovasc Med; 2024 Jul; 34(5):279-285. PubMed ID: 37015297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of five positive control drugs in hERG external solution (buffer) by LC-MS/MS to support in vitro hERG assay as recommended by ICH S7B.
    King TI; Indapurkar A; Tariq I; DePalma R; Mistry S; Alvarez-Baron C; Ismaiel OA; Wu W; Chiu K; Patel V; Rouse R; Strauss DG; Matta MK
    J Pharmacol Toxicol Methods; 2022; 118():107229. PubMed ID: 36334898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
    Qu Y; Fang M; Gao B; Chui RW; Vargas HM
    J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized J to T peak and T peak to T end measurements in nonclinical species administered moxifloxacin and amiodarone.
    Bartko TM; Lutgen SM; Ross RA; Walisser JA; Garske EP; Kopelke KR; Ashcroft-Hawley K; Tang HM; Kremer JJ; Friedrichs GS; Nichols JV
    J Pharmacol Toxicol Methods; 2024; 128():107527. PubMed ID: 38852685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
    Kongsamut S; Kang J; Chen XL; Roehr J; Rampe D
    Eur J Pharmacol; 2002 Aug; 450(1):37-41. PubMed ID: 12176106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
    Qu Y; Gao B; Fang M; Vargas HM
    J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.
    Vicente J; Johannesen L; Mason JW; Crumb WJ; Pueyo E; Stockbridge N; Strauss DG
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25870186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of ascending dose canine telemetry model supports its use in E14/S7B QT integrated risk assessments.
    Chaves AA; Ferraro JW; Yu J; Moye MJ; Yee KL; Li F; Steve DL; Lengel DJ; Regan CP
    J Pharmacol Toxicol Methods; 2024; 128():107525. PubMed ID: 38851600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation and Clinical Utility of the hERG IC50:C
    Lehmann DF; Eggleston WD; Wang D
    Pharmacotherapy; 2018 Mar; 38(3):341-348. PubMed ID: 29380488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.